Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone...

Area of Science:

• Oncology
• Molecular Biology
• Bone Biology

Background:

• Osteosarcoma (OS) is the most common primary bone cancer.
• OS exhibits high heterogeneity and resistance to standard treatments due to microenvironment survival signals.
• The c-MET oncogene is implicated in OS initiation and progression.

Purpose of the Study:

• To evaluate the efficacy of cabozantinib (CBZ), a c-MET inhibitor, against OS.
• To investigate CBZ's direct effects on OS cells.
• To assess CBZ's impact on the bone tumor microenvironment.

Main Methods:

• In vitro models of OS were treated with varying doses of CBZ.
• Co-culture systems with bone cells were used to mimic the OS-tumor microenvironment.
• ERK and AKT signaling pathways were analyzed.
• Osteoprotegerin and RANK ligand production by osteoblasts were measured.

Main Results:

• CBZ significantly decreased OS cell proliferation and migration.
• CBZ inhibited ERK and AKT signaling pathways in OS cells.
• CBZ reduced proliferation of receptor activator of nuclear factor κB (RANK)-expressing OS cells.
• CBZ modulated the bone microenvironment by increasing osteoprotegerin and decreasing RANK ligand production.

Conclusions:

• Cabozantinib (CBZ) demonstrates potential as a novel therapeutic agent for osteosarcoma.
• CBZ exerts its effects by targeting OS cells directly and influencing the bone microenvironment.
• RANK expression on OS cells may serve as a predictive biomarker for treatment response to CBZ.